
Opinion|Videos|July 29, 2024
Ongoing Research in Hidradenitis Suppurativa
Author(s)Vivian Shi, MD, FAAD
An expert on hidradenitis suppurativa gives an overview of the current research landscape, highlighting exciting developments in the treatment space.
Advertisement
Episodes in this series

Video content above is prompted by the following question:
- What are the other investigational agents for hidradenitis suppurativa (HS) that you are excited about and what is their stage in development?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Belantamab Mafodotin Combo for Relapsed or Refractory Multiple Myeloma
2
IEHP CEO Weighs in: Who Pays the Price When Millions Lose Medicaid Coverage?
3
Guidelines for Bronchiectasis Highlight Multiple Treatment Methods
4
Belantamab Mafodotin Can Help Fill Access Gaps in BCMA-Directed Myeloma Therapy: Hearn Jay Cho, MD, PhD
5















































